Clenergy Technology (603628.SH) plans to grant 1.9647 million restricted stocks with a grant price of 6.5 yuan per share.
Qingyuan Stock (603628.SH) disclosed the 2024 Restricted Stock Incentive Plan (Draft), the company plans to grant...
Clenergy Technology (603628.SH) disclosed the 2024 restricted stock incentive plan (draft), with a proposed grant of 1.9647 million restricted stocks (initial grant of 1.7647 million stocks, with 0.2 million stocks reserved), at a grant price of 6.50 yuan per share. The initial grant of incentive targets 89 individuals.
In addition, the term of this incentive plan is from the date of initial registration of the restricted stocks until the date when all restricted stocks granted to incentive targets are fully released from restrictions or repurchased and canceled, not exceeding 60 months.
Related Articles

GENES TECH (08257) temporarily suspended trading in the morning of November 5th pending the publication of insider information.

ZENERGY (03677) Safeguards Aviation-Grade Standard Batteries to Support GAC Toyota in Taking Responsibility for Battery Degradation, Defining Service New Benchmarks.

Chongqing Sokon Industry Group Stock (09927) raised 14 billion Hong Kong dollars in its Hong Kong Stock Exchange listing today, making it the "first A+H luxury new energy vehicle company".
GENES TECH (08257) temporarily suspended trading in the morning of November 5th pending the publication of insider information.

ZENERGY (03677) Safeguards Aviation-Grade Standard Batteries to Support GAC Toyota in Taking Responsibility for Battery Degradation, Defining Service New Benchmarks.

Chongqing Sokon Industry Group Stock (09927) raised 14 billion Hong Kong dollars in its Hong Kong Stock Exchange listing today, making it the "first A+H luxury new energy vehicle company".

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


